Web4 mai 2024 · Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on May 4. The trial is evaluating motixafortide in combination with granulocyte colony-stimulating factor (G-CSF) in stem-cell … Web14 iun. 2024 · Maxim Group’s Jason McCarthy is bullish on cancer specialist Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) on the strength of its leukemia drug pipeline... This website uses cookies. We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about …
Maxim Group Initiates Coverage of Mind Cure Health
Web26 mai 2024 · The panel will include an interactive discussion moderated by Jason McCarthy, Ph.D., Maxim Group Senior Managing Director, Biotechnology. WebJason McCarthy, Ph.D. is a Senior Managing Director covering the biotechnology industry at Maxim Group. Dr. McCarthy joined Maxim Group in July 2014. Prior to joining … section 27 of banking act
Maxim ups Annovis Bio PT to $45 from $12 - BioTuesdays
Web13 mai 2024 · Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s. Kilmer Lucas; ... writes analyst Jason McCarthy, Ph.D., adding that the PD data are a positive for ANVS401, which is an oral drug designed to mitigate neural inflammation and … WebAcum 1 zi · ContraFect (CFRX – Research Report) received a Buy rating and a $3.00 price target from Maxim Group analyst Jason McCarthy today. The company’s shares … WebAcum 1 zi · ContraFect (CFRX – Research Report) received a Buy rating and a $3.00 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $1.01. McCarthy ... pure iptv application